Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s, and affects more than 1% of the population. Basically it is characterised by the loss of nigral dopaminergic neurons, which results in the presence of severe motor symptoms. However, other cerebral areas are also altered, producing a range of non-motor symptoms that include olfactory dysfunction, sleep disorder, depression, anxiety, hallucinations, fatigue, cognitive deficiency and dementia. Current treatments are symptomatic, most of them modulating the activity of motor circuits. This lecture will focus on the development of new therapeutic strategies designed to reduce the progression of the disease.
Streaming:
http://www.streamingbarcelona.com/plataforma/residenciainvestigadors/
Institut d'Investigacions Biomèdiques de Barcelona (IIBB - CSIC)
Institut Català de Nanociència i Nanotecnologia (ICN2)